L
Larimar Therapeutics, Inc.
LRMR · NASDAQ · Healthcare · 453M
Price · close
$4.18
+0.48% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
—
Price / net assetsP/B
3.9×
Enterprise value / EBITDAEV/EBITDA
-1.4×
Free cash flow yieldFCF yield
-37.2%
Return on equityROE
-212.2%
Operating margin
—
Net debt / EBITDAbalance-sheet strength
0.5×
Interest coverage
—
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.